clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease research hub

Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of one dose (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in decompensated cirrhosis after their first decompensation event, who are stabilized CTP 5-7

This study looks at a new medicine called BI 685509 for people with liver disease and high blood pressure in their liver (portal hypertension). We want to see if it lowers this pressure after 8 weeks, helping to prevent serious complications.